Clobetasol propionate--where, when, why?
- PMID: 18806904
- DOI: 10.1358/dot.2008.44.7.1122221
Clobetasol propionate--where, when, why?
Abstract
Clobetasol propionate is the most potent of all topical steroids. It is successfully applied in the treatment of various skin diseases such as atopic dermatitis, psoriasis and vulvar lichen sclerosus. The therapy is, however, mainly symptomatic. A preventive effect is only reported in the treatment of the latter. Clobetasol propionate exerts antiinflammatory, immunosuppressive and antimitotic effects influencing the growth, differentiation and function of various cells and inhibiting cytokine production. Seven different dosage forms are available to deliver the drug to the living cells of the skin. Their choice might additionally affect patient compliance. The potency of clobetasol propionate, however, is accompanied by local and systemic side effects, such as skin atrophy and hypothalamic-pituitary-adrenal axis suppression. Patients applying clobetasol propionate must be well instructed in how to use it. Physicians prescribing clobetasol propionate should consider a diversity of factors and be able to answer the questions where, when and why.
Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.J Am Acad Dermatol. 2008 Sep;59(3):448-54, 454.e1. doi: 10.1016/j.jaad.2008.04.020. Epub 2008 Jun 9. J Am Acad Dermatol. 2008. PMID: 18539358 Clinical Trial.
-
Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.Cutis. 2012 Feb;89(2):89-94. Cutis. 2012. PMID: 22474733 Review.
-
A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus.J Am Acad Dermatol. 2014 Jul;71(1):84-91. doi: 10.1016/j.jaad.2014.02.019. Epub 2014 Apr 3. J Am Acad Dermatol. 2014. PMID: 24704090 Clinical Trial.
-
Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.Cutis. 2009 Oct;84(4 Suppl):25-32. Cutis. 2009. PMID: 19916299 Clinical Trial.
-
Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses.Expert Opin Pharmacother. 2008 Aug;9(11):2001-7. doi: 10.1517/14656566.9.11.2001. Expert Opin Pharmacother. 2008. PMID: 18627337 Review.
Cited by
-
Poly(lactic Acid) Fibers for Sustained Drug Delivery: Insights into Release Profiles and Cellular Interactions.Materials (Basel). 2025 May 27;18(11):2532. doi: 10.3390/ma18112532. Materials (Basel). 2025. PMID: 40508529 Free PMC article.
-
Evaluation of Clobetasol and Tacrolimus Treatments in an Imiquimod-Induced Psoriasis Rat Model.Int J Mol Sci. 2024 Aug 26;25(17):9254. doi: 10.3390/ijms25179254. Int J Mol Sci. 2024. PMID: 39273201 Free PMC article.
-
Topical corticosteroid-induced skin atrophy: a comprehensive review.Drug Saf. 2015 May;38(5):493-509. doi: 10.1007/s40264-015-0287-7. Drug Saf. 2015. PMID: 25862024 Review.
-
Different Treatment Modalities of Oral Lichen Planus-A Narrative Review.Dent J (Basel). 2023 Jan 12;11(1):26. doi: 10.3390/dj11010026. Dent J (Basel). 2023. PMID: 36661563 Free PMC article. Review.
-
Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.Endocrine. 2010 Dec;38(3):328-34. doi: 10.1007/s12020-010-9393-6. Epub 2010 Oct 23. Endocrine. 2010. PMID: 20972726 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical